Dexmedetomidine for sedation in the ICU or PICU: a review of cost-effectiveness and guidelines
CADTH
Record ID 32016000162
English
Authors' recommendations:
Six economic evaluations and two guidelines were included in this review. All except one economic study showed that dexmedetomidine was associated with lower ICU and hospital costs. However, the clinical benefits were marginal and not consistent in the included studies. The included guidelines suggested that the use of dexmedetomidine might be preferred over the benzodiazepine sedatives for better clinical outcomes and lower risk of delirium.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
http://www.cadth.ca/sites/default/files/pdf/htis/jan-2015/RC0617_Dexmedetomidine%20final.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Critical Care
- Dexmedetomidine
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.